Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity	
----------------	--

## Gold Mountain Limited

79 115 815 942

We (the entity) give ASX the following information.

#### Part 1 - All issues

ABN

You must complete the relevant sections (attach sheets if there is not enough space).

<sup>1</sup> +Class of +securities issued or to be issued

Ordinary Shares (GMN)

Number of \*securities issued or to be issued (if known) or maximum number which may be issued

8,400,000

Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

**Fully Paid Ordinary Shares** 

(Entitlement of unlisted options of one 10c 12-month option and one 15c 24-month option for every 2 issued placement shares to be issued after 2019 AGM)

<sup>+</sup> See chapter 19 for defined terms.

Do the \*securities rank equally in 4 all respects from the +issue date Shares rank equally with all other fully paid with an existing +class of quoted ordinary shares. +securities? If the additional \*securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Issue price or consideration 5 8,400,000 Shares at \$0.06 (Total: \$504,000.00) 6 Purpose of the issue Working capital (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Is the entity an +eligible entity Yes that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the \*securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder 30 November 2018 resolution under rule 7.1A was passed 6c Number of \*securities issued nil without security holder approval under rule 7.1 6d Number of \*securities issued 8,400,000 with security holder approval under rule 7.1A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) 6f Number of \*securities issued

Nil

under an exception in rule 7.2

Nil

6g If \*securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.

N/A

Securities issued under rule 7.1A were issued at least 75% of the 15-days VWAP as calculated under rule 7.1A3

- Issued Price: \$0.06 - 15-days VWAP: \$0.067

Data Source: ASX

6h If \*securities were issued under 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

N/A

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

Rule 7.1 nil

Rule 7.1A 68,230

7 +Issue dates

> Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

25 October 2019

8 Number and +class of all <sup>+</sup>securities quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
609,849,859	Ordinary Shares
(including 22,000,000 shares under voluntary escrow due for release on 28/11/2019)	

Appendix 3B Page 3 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)

Number	+Class
14,800,000	Options (ESOP) at exercise price \$0.30 expiring 28/11/2019 (Code: GMNAB)
2,000,000	Options (Participating Directors) at exercise price \$0.15 expiring 26/7/2021 with vesting conditions (Code: GMNAD)
7,800,000	Options (ESOP) at exercise price \$0.15 expiring 26/7/2021 with vesting conditions (Code: GMNAE)
10,148,462 7,138,461 9,866,669	Options at exercise price \$0.10 expiring 1/3/2020 - expiring 27/5/2020 - expiring 28/8/2020
10,148,462 7,138,461 9,866,669	Options at exercise price \$0.15 expiring 1/3/2021 - expiring 27/5/2021 - expiring 28/8/2021

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

No change			

#### Part 2 - Pro rata issue

11	Is security holder approval required?
12	Is the issue renounceable or non-renounceable?
13	Ratio in which the *securities will be offered
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates
15	<sup>+</sup> Record date to determine entitlements

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

	_	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
	L	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
22	ivaliles of any brokers to the issue	
	_	
23	Fee or commission payable to the broker to the issue	
2.4	Amount of any handling fee	
<b>2</b> 4	payable to brokers who lodge	
	acceptances or renunciations on behalf of security holders	
	If the issue is continuous on [	
25	If the issue is contingent on security holders' approval, the date of the meeting	
_		
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
	TC .1	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise,	
	the date on which notices will be	

<sup>+</sup> See chapter 19 for defined terms.

28	Date rights trading will begin (if applicable)
29	Date rights trading will end (if applicable)
30	How do security holders sell their entitlements in full through a broker?
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?
32	How do security holders dispose of their entitlements (except by sale through a broker)?
33	<sup>+</sup> Issue date
	<b>3 - Quotation of securities</b> If only complete this section if you are applying for quotation of securities  Type of *securities
	(tick one)
(a)	X *Securities described in Part 1
(b)	All other *securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully pai employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertib securities
Entitie	s that have ticked box 34(a)
Additi	onal securities forming a new class of securities
Tick to docum	indicate you are providing the information or ents

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders	
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories  1 - 1,000  1,001 - 5,000  5,001 - 10,000  10,001 - 100,000  100,001 and over	
37	A copy of any trust deed for the additional *securities	
Entitie	s that have ticked box 34(b)	
38	Number of *securities for which *quotation is sought	
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	

<sup>+</sup> See chapter 19 for defined terms.

41	Reason for request for quotation now	
	Example: In the case of restricted securities, end of restriction period	
	(if issued upon conversion of another *security, clearly identify that other *security)	

Number and \*class of all \*securities quoted on ASX (including the \*securities in clause 38)

Number	+Class

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 24 October 2019

(Director/Company Secretary)

Print name: Eric Kam. == == == ==

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	515,142,680	
Add the following:		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid *ordinary securities that became fully paid in that 12 month period		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	Nil	
"A"	515,142,680	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"			
"B"	0.15 [Note: this value cannot be changed]		
<b>Multiply</b> "A" by 0.15	77,271,402		
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used			
Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:	10,148,462 (28/2/19) 10,148,462 (28/2/19)		
<ul><li>Under an exception in rule 7.2</li><li>Under rule 7.1A</li></ul>	14,276,923 (24/5/19) 7,138,461 (24/5/19)		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	7,138,461 (24/5/19) 9,866,669 (29/8/19) 9,866,669 (29/8/19) 8,687,295 (29/8/19)		
"C"	77,271,402		
Step 4: Subtract "C" from ["A" x ' placement capacity under rule 7.1	-		
"A" x 0.15 Note: number must be same as shown in Step 2	77,271,402		
Subtract "C"  Note: number must be same as shown in Step 3	77,271,402		
<i>Total</i> ["A" x 0.15] – "C"	nil [Note: this is the remaining placement capacity under rule 7.1]		

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	515,142,680	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	51,514,268	
Step 3: Calculate "E", the amount of pl 7.1A that has already been used  Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	13,046,038 (29/8/19)	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	30,000,000 <i>(5/9/19)</i> 8,400,000	
"E"	51,446,038	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10 Note: number must be same as shown in Step 2	51,514,268
Subtract "E"  Note: number must be same as shown in Step 3	51,446,038
<i>Total</i> ["A" x 0.10] – "E"	68,230  Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.